Title:
ＩＡＰアンタゴニスト及び抗ＰＤ－１分子による併用抗癌療法
Document Type and Number:
Japanese Patent JP7438947
Kind Code:
B2
Abstract:
Disclosed is the use of an IAP antagonist for pretreating a human subject diagnosed with a cancer to enhance the likelihood that a subsequent treatment with an anti-PD-1 molecule results in an anti-cancer response or to enhance the responsiveness of the subject's cancer to the subsequent treatment with the anti-PD-1 molecule. Also encompassed are methods of treatment of a subject's cancer, the methods comprising pretreatment of the subject with an IAP antagonist and subsequent treatment of the subject with an anti-PD-1 molecule.
Inventors:
Beaunio, Gregoire
Weedemann, Norbert
Gavier, Bruno
Schildagemazin Altman, Sergio Adrian
Weedemann, Norbert
Gavier, Bruno
Schildagemazin Altman, Sergio Adrian
Application Number:
JP2020532019A
Publication Date:
February 27, 2024
Filing Date:
December 21, 2018
Export Citation:
Assignee:
Debio Farm International SA.
International Classes:
A61K31/407; A61K31/5377; A61K38/05; A61K38/06; A61K39/395; A61K45/06; A61P35/00; A61P37/04; A61P43/00
Other References:
BO LU,ROLE OF SMAC IN LUNG CARCINOGENESIS AND THERAPY,【ONLINE】,2017年07月,PAGE(S):1- 5,https://apps.dtic.mil/sti/citations/AD1050348
SHAWN T BEUG; ET AL,SMAC MIMETICS SYNERGIZE WITH IMMUNE CHECKPOINT INHIBITORS TO PROMOTE TUMOUR 以下備考,NATURE COMMUNICATIONS,2017年02月15日,VOL:8,PAGE(S):1-15,http://dx.doi.org/10.1038/ncomms14278,IMMUNITY AGAINST GLIOBLASTOMA
SHAWN T BEUG; ET AL,SMAC MIMETICS SYNERGIZE WITH IMMUNE CHECKPOINT INHIBITORS TO PROMOTE TUMOUR 以下備考,NATURE COMMUNICATIONS,2017年02月15日,VOL:8,PAGE(S):1-15,http://dx.doi.org/10.1038/ncomms14278,IMMUNITY AGAINST GLIOBLASTOMA
Attorney, Agent or Firm:
Yoshiyuki Inaba
Toshifumi Onuki
Akihiko Eguchi
Kazuhiko Naito
Toshifumi Onuki
Akihiko Eguchi
Kazuhiko Naito
Previous Patent: Adjustable prism for optical image stabilization
Next Patent: Smoking alternative consumables
Next Patent: Smoking alternative consumables